Effects of Oral Zinc Gluconate Among Acne Vulgaris Patients

NCT ID: NCT05096312

Last Updated: 2022-05-11

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

23 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-12-21

Study Completion Date

2019-07-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Acne Vulgaris is one of the most common dermatologic diagnoses requiring long-term maintenance therapy. Promising results of oral zinc gluconate in improving acne vulgaris has been described.

A randomized, double blind, placebo-controlled clinical trial was utilized for this study with the objective to assess the efficacy of oral zinc gluconate in the improvement of disease activity in acne vulgaris patients as measured by the inflammatory score and Global Acne Grading System (GAGS) score.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Acne has four main pathogenic contributors: follicular hyperkeratinization, increased sebum production, Propionibacterium acnes (P. acnes) within the follicle, and inflammation. Treatment options for acne vulgaris include benzoyl peroxide, topical and oral retinoids, topical and oral antimicrobials, oral corticosteroids, and physical modalities such as acne surgery, laser and light therapy. Reports show that antibiotic resistance is a growing issue in the treatment regimen of acne vulgaris, making it less and less suitable for long-term treatment, hence other options that can be substitutes or adjuncts to treatment may be useful in this condition. For long-term or maintenance therapy, physicians should consider effectivity, cost, and adverse effects. Several studies have explored the effect of oral zinc on acne vulgaris. Since zinc is more cost-effective and has less adverse effects compared to most antibiotics, this may prove helpful for the Filipino patient in terms of safety and economy for long-term therapy.

The aim of this study is to assess the efficacy of oral zinc gluconate in the improvement of disease activity in acne vulgaris patients, to determine the demographic and clinical profile of Acne Vulgaris patients, to determine the disease activity measured by the inflammatory score and GAGS score of acne vulgaris patients on initial consult, at 4 weeks, and at 8 weeks, and to determine if there is a significant difference in disease activity as measured by the inflammatory score and GAGS score among acne vulgaris patients given placebo and oral zinc gluconate.

A randomized, double blind, placebo-controlled clinical trial was utilized. Adults with moderate to severe acne vulgaris were included in the study. Patients were evaluated using the inflammatory score and Global Acne Grading System (GAGS) at the start, at midpoint, and at the end of the trial. One group of participants received zinc gluconate supplementation and another group received placebo for 60 days. All participants received topical adapalene 0.3% + Benzoyl peroxide 2.5% gel applied once daily in the evening. Improvement in acne severity was then determined and compared.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acne Vulgaris

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Zinc gluconate group

interventions: Zinc gluconate (200g/capsule) one capsule once in the morning after breakfast for 60 days.

Adapalene 0.3% + benzoyl peroxide 2.5% gel to be applied once at night for 60 days.

Group Type ACTIVE_COMPARATOR

Zinc gluconate

Intervention Type DIETARY_SUPPLEMENT

oral zinc gluconate 200mg

Adapalene 0.003 MG/MG / Benzoyl Peroxide 0.025 MG/MG Topical Gel [Epiduo]

Intervention Type DRUG

Adapalene 0.3% + Benzoyl peroxide 2.5% gel applied once daily in the evening

Placebo group

interventions: Placebo capsule, one capsule once in the morning after breakfast for 60 days. Adapalene 0.3% + benzoyl peroxide 2.5% gel to be applied once at night for 60 days.

Group Type PLACEBO_COMPARATOR

Adapalene 0.003 MG/MG / Benzoyl Peroxide 0.025 MG/MG Topical Gel [Epiduo]

Intervention Type DRUG

Adapalene 0.3% + Benzoyl peroxide 2.5% gel applied once daily in the evening

Placebo

Intervention Type OTHER

contains cornstarch

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Zinc gluconate

oral zinc gluconate 200mg

Intervention Type DIETARY_SUPPLEMENT

Adapalene 0.003 MG/MG / Benzoyl Peroxide 0.025 MG/MG Topical Gel [Epiduo]

Adapalene 0.3% + Benzoyl peroxide 2.5% gel applied once daily in the evening

Intervention Type DRUG

Placebo

contains cornstarch

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Solgar zinc gluconate Epiduo Forte

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Filipino patients, aged 18-27 years old
* New patients diagnosed with Acne Vulgaris with a Global Acne Grading System score of at least 19
* Able to read and write in English or Tagalog
* Seen at the Dermatology out-patient clinic of East Avenue Medical Center

Exclusion Criteria

* Patients with other chronic dermatoses or systemic disease
* Taking oral supplements or medications within the past 4 weeks
* Patients who are pregnant or lactating
Minimum Eligible Age

18 Years

Maximum Eligible Age

27 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

East Avenue Medical Center, Philippines

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Monique Lianne C. Lim-Ang, MD, MBA, DPDS

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Monique Lianne C. Lim-Ang, MD,MBA,DPDS

Role: PRINCIPAL_INVESTIGATOR

East Avenue Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

East Avenue Medical Center

Quezon City, National Capital Region, Philippines

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Philippines

References

Explore related publications, articles, or registry entries linked to this study.

Verma KC, Saini AS, Dhamija SK. Oral zinc sulphate therapy in acne vulgaris: a double-blind trial. Acta Derm Venereol. 1980;60(4):337-40. doi: 10.2340/0001555560337340.

Reference Type BACKGROUND
PMID: 6163281 (View on PubMed)

Sardana K, Garg VK. An observational study of methionine-bound zinc with antioxidants for mild to moderate acne vulgaris. Dermatol Ther. 2010 Jul-Aug;23(4):411-8. doi: 10.1111/j.1529-8019.2010.01342.x.

Reference Type BACKGROUND
PMID: 20666829 (View on PubMed)

Vahlquist A, Michaelsson G, Juhlin L. Acne treatment with oral zinc and vitamin A: effects on the serum levels of zinc and retinol binding protein (RBP). Acta Derm Venereol. 1978;58(5):437-42.

Reference Type BACKGROUND
PMID: 82355 (View on PubMed)

Dreno B, Foulc P, Reynaud A, Moyse D, Habert H, Richet H. Effect of zinc gluconate on propionibacterium acnes resistance to erythromycin in patients with inflammatory acne: in vitro and in vivo study. Eur J Dermatol. 2005 May-Jun;15(3):152-5.

Reference Type BACKGROUND
PMID: 15908296 (View on PubMed)

Jarrousse V, Castex-Rizzi N, Khammari A, Charveron M, Dreno B. Zinc salts inhibit in vitro Toll-like receptor 2 surface expression by keratinocytes. Eur J Dermatol. 2007 Nov-Dec;17(6):492-6. doi: 10.1684/ejd.2007.0263. Epub 2007 Oct 19.

Reference Type BACKGROUND
PMID: 17951128 (View on PubMed)

Bhate K, Williams HC. Epidemiology of acne vulgaris. Br J Dermatol. 2013 Mar;168(3):474-85. doi: 10.1111/bjd.12149.

Reference Type BACKGROUND
PMID: 23210645 (View on PubMed)

Humphrey S. Antibiotic resistance in acne treatment. Skin Therapy Lett. 2012 Oct;17(9):1-3.

Reference Type BACKGROUND
PMID: 23032935 (View on PubMed)

Tan JK, Bhate K. A global perspective on the epidemiology of acne. Br J Dermatol. 2015 Jul;172 Suppl 1:3-12. doi: 10.1111/bjd.13462.

Reference Type BACKGROUND
PMID: 25597339 (View on PubMed)

Collier CN, Harper JC, Cafardi JA, Cantrell WC, Wang W, Foster KW, Elewski BE. The prevalence of acne in adults 20 years and older. J Am Acad Dermatol. 2008 Jan;58(1):56-9. doi: 10.1016/j.jaad.2007.06.045. Epub 2007 Oct 22.

Reference Type BACKGROUND
PMID: 17945383 (View on PubMed)

Goulden V, Stables GI, Cunliffe WJ. Prevalence of facial acne in adults. J Am Acad Dermatol. 1999 Oct;41(4):577-80.

Reference Type BACKGROUND
PMID: 10495379 (View on PubMed)

Thiboutot DM, Dreno B, Abanmi A, Alexis AF, Araviiskaia E, Barona Cabal MI, Bettoli V, Casintahan F, Chow S, da Costa A, El Ouazzani T, Goh CL, Gollnick HPM, Gomez M, Hayashi N, Herane MI, Honeyman J, Kang S, Kemeny L, Kubba R, Lambert J, Layton AM, Leyden JJ, Lopez-Estebaranz JL, Noppakun N, Ochsendorf F, Oprica C, Orozco B, Perez M, Piquero-Martin J, See JA, Suh DH, Tan J, Lozada VT, Troielli P, Xiang LF. Practical management of acne for clinicians: An international consensus from the Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2018 Feb;78(2 Suppl 1):S1-S23.e1. doi: 10.1016/j.jaad.2017.09.078. Epub 2017 Nov 8.

Reference Type BACKGROUND
PMID: 29127053 (View on PubMed)

Stein Gold L, Weiss J, Rueda MJ, Liu H, Tanghetti E. Moderate and Severe Inflammatory Acne Vulgaris Effectively Treated with Single-Agent Therapy by a New Fixed-Dose Combination Adapalene 0.3 %/Benzoyl Peroxide 2.5 % Gel: A Randomized, Double-Blind, Parallel-Group, Controlled Study. Am J Clin Dermatol. 2016 Jun;17(3):293-303. doi: 10.1007/s40257-016-0178-4.

Reference Type BACKGROUND
PMID: 26945741 (View on PubMed)

Al-Shobaili HA. Oxidants and anti-oxidants status in acne vulgaris patients with varying severity. Ann Clin Lab Sci. 2014 Spring;44(2):202-7.

Reference Type BACKGROUND
PMID: 24795060 (View on PubMed)

Bray TM, Bettger WJ. The physiological role of zinc as an antioxidant. Free Radic Biol Med. 1990;8(3):281-91. doi: 10.1016/0891-5849(90)90076-u.

Reference Type BACKGROUND
PMID: 2187766 (View on PubMed)

Prasad AS. Zinc is an Antioxidant and Anti-Inflammatory Agent: Its Role in Human Health. Front Nutr. 2014 Sep 1;1:14. doi: 10.3389/fnut.2014.00014. eCollection 2014.

Reference Type BACKGROUND
PMID: 25988117 (View on PubMed)

Rostan EF, DeBuys HV, Madey DL, Pinnell SR. Evidence supporting zinc as an important antioxidant for skin. Int J Dermatol. 2002 Sep;41(9):606-11. doi: 10.1046/j.1365-4362.2002.01567.x.

Reference Type BACKGROUND
PMID: 12358835 (View on PubMed)

Sardana K, Chugh S, Garg VK. The role of zinc in acne and prevention of resistance: have we missed the "base" effect? Int J Dermatol. 2014 Jan;53(1):125-7. doi: 10.1111/ijd.12264. No abstract available.

Reference Type BACKGROUND
PMID: 24350859 (View on PubMed)

Buxaderas SC, Farre-Rovira R. Whole blood and serum zinc levels in relation to sex and age. Rev Esp Fisiol. 1985 Dec;41(4):463-70.

Reference Type BACKGROUND
PMID: 4095368 (View on PubMed)

Amer M, Bahgat MR, Tosson Z, Abdel Mowla MY, Amer K. Serum zinc in acne vulgaris. Int J Dermatol. 1982 Oct;21(8):481-4. doi: 10.1111/j.1365-4362.1982.tb03188.x.

Reference Type BACKGROUND
PMID: 6217164 (View on PubMed)

Arora PN, Dhillon KS, Rajan SR, Sayal SK, Das AL. Serum Zinc Levels in Cutaneous Disorders. Med J Armed Forces India. 2002 Oct;58(4):304-6. doi: 10.1016/S0377-1237(02)80083-1. Epub 2011 Jul 21.

Reference Type BACKGROUND
PMID: 27407419 (View on PubMed)

Rostami Mogaddam M, Safavi Ardabili N, Maleki N, Soflaee M. Correlation between the severity and type of acne lesions with serum zinc levels in patients with acne vulgaris. Biomed Res Int. 2014;2014:474108. doi: 10.1155/2014/474108. Epub 2014 Jul 24.

Reference Type BACKGROUND
PMID: 25157359 (View on PubMed)

Michaelsson G, Vahlquist A, Juhlin L. Serum zinc and retinol-binding protein in acne. Br J Dermatol. 1977 Mar;96(3):283-6. doi: 10.1111/j.1365-2133.1977.tb06138.x.

Reference Type BACKGROUND
PMID: 139912 (View on PubMed)

Ozuguz P, Dogruk Kacar S, Ekiz O, Takci Z, Balta I, Kalkan G. Evaluation of serum vitamins A and E and zinc levels according to the severity of acne vulgaris. Cutan Ocul Toxicol. 2014 Jun;33(2):99-102. doi: 10.3109/15569527.2013.808656. Epub 2013 Jul 5.

Reference Type BACKGROUND
PMID: 23826827 (View on PubMed)

Gupta M, Mahajan VK, Mehta KS, Chauhan PS. Zinc therapy in dermatology: a review. Dermatol Res Pract. 2014;2014:709152. doi: 10.1155/2014/709152. Epub 2014 Jul 10.

Reference Type BACKGROUND
PMID: 25120566 (View on PubMed)

Bae YS, Hill ND, Bibi Y, Dreiher J, Cohen AD. Innovative uses for zinc in dermatology. Dermatol Clin. 2010 Jul;28(3):587-97. doi: 10.1016/j.det.2010.03.006.

Reference Type BACKGROUND
PMID: 20510767 (View on PubMed)

Bibi Nitzan Y, Cohen AD. Zinc in skin pathology and care. J Dermatolog Treat. 2006;17(4):205-10. doi: 10.1080/09546630600791434.

Reference Type BACKGROUND
PMID: 16971312 (View on PubMed)

Michaelsson G, Juhlin L, Ljunghall K. A double-blind study of the effect of zinc and oxytetracycline in acne vulgaris. Br J Dermatol. 1977 Nov;97(5):561-6. doi: 10.1111/j.1365-2133.1977.tb14136.x.

Reference Type BACKGROUND
PMID: 145237 (View on PubMed)

Dreno B, Moyse D, Alirezai M, Amblard P, Auffret N, Beylot C, Bodokh I, Chivot M, Daniel F, Humbert P, Meynadier J, Poli F; Acne Research and Study Group. Multicenter randomized comparative double-blind controlled clinical trial of the safety and efficacy of zinc gluconate versus minocycline hydrochloride in the treatment of inflammatory acne vulgaris. Dermatology. 2001;203(2):135-40. doi: 10.1159/000051728.

Reference Type BACKGROUND
PMID: 11586012 (View on PubMed)

Cunliffe WJ, Burke B, Dodman B, Gould DJ. A double-blind trial of a zinc sulphate/citrate complex and tetracycline in the treatment of acne vulgaris. Br J Dermatol. 1979 Sep;101(3):321-5. doi: 10.1111/j.1365-2133.1979.tb05626.x.

Reference Type BACKGROUND
PMID: 159714 (View on PubMed)

Dreno B, Amblard P, Agache P, Sirot S, Litoux P. Low doses of zinc gluconate for inflammatory acne. Acta Derm Venereol. 1989;69(6):541-3.

Reference Type BACKGROUND
PMID: 2575335 (View on PubMed)

Hillstrom L, Pettersson L, Hellbe L, Kjellin A, Leczinsky CG, Nordwall C. Comparison of oral treatment with zinc sulphate and placebo in acne vulgaris. Br J Dermatol. 1977 Dec;97(6):681-4. doi: 10.1111/j.1365-2133.1977.tb14277.x.

Reference Type BACKGROUND
PMID: 146511 (View on PubMed)

Goransson K, Liden S, Odsell L. Oral zinc in acne vulgaris: a clinical and methodological study. Acta Derm Venereol. 1978;58(5):443-8.

Reference Type BACKGROUND
PMID: 82356 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Related Links

Access external resources that provide additional context or updates about the study.

https://bijps.uobaghdad.edu.iq/index.php/bijps/article/view/474

Serum Trace Elements (Zinc, Copper and Magnesium) Status in Iraqi Patients with Acne Vulgaris: (Case- Controlled Study)

http://scinet.science.ph/union/Downloads/Fil-361265_361265.pdf

A Cross-Sectional Study on the Impact of Acne Vulgaris on the Quality of Life among High School Students in Pasig City, Philippines

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

EAMC IERB 2018-52

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Experience With Topical Acne Treatment
NCT05582434 ACTIVE_NOT_RECRUITING EARLY_PHASE1